Valiant Laboratories Ltd
Incorporated in 1980, Valiant Laboratories Limited is a pharmaceutical ingredient manufacturing company in India having focuses on manufacturing Paracetamol.[1]
- Market Cap ₹ 614 Cr.
- Current Price ₹ 141
- High / Low ₹ 227 / 129
- Stock P/E 1,806
- Book Value ₹ 54.5
- Dividend Yield 0.00 %
- ROCE -0.29 %
- ROE 0.20 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Earnings include an other income of Rs.9.68 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
182 | 292 | 334 | 182 | |
132 | 249 | 299 | 190 | |
Operating Profit | 50 | 42 | 35 | -8 |
OPM % | 27% | 15% | 11% | -5% |
1 | 2 | 5 | 10 | |
Interest | 2 | 0 | 0 | 0 |
Depreciation | 3 | 2 | 2 | 2 |
Profit before tax | 47 | 42 | 38 | -1 |
Tax % | 35% | 34% | 24% | 145% |
31 | 28 | 29 | 0 | |
EPS in Rs | 16.89 | 8.91 | 0.08 | |
Dividend Payout % | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 0% |
TTM: | -45% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -78% |
TTM: | -99% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 17% |
Last Year: | 0% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
Equity Capital | 10 | 16 | 33 | 43 |
Reserves | 78 | 55 | 68 | 193 |
1 | 61 | 60 | 60 | |
17 | 49 | 52 | 28 | |
Total Liabilities | 106 | 182 | 213 | 325 |
20 | 22 | 30 | 32 | |
CWIP | 0 | 1 | 0 | 0 |
Investments | 0 | 0 | 34 | 119 |
87 | 158 | 149 | 174 | |
Total Assets | 106 | 182 | 213 | 325 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
9 | 2 | 23 | 49 | |
-17 | -12 | -21 | -183 | |
11 | 6 | -2 | 136 | |
Net Cash Flow | 4 | -4 | 0 | 2 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
Debtor Days | 85 | 139 | 97 | 92 |
Inventory Days | 18 | 25 | 17 | 22 |
Days Payable | 37 | 72 | 62 | 54 |
Cash Conversion Cycle | 66 | 91 | 52 | 60 |
Working Capital Days | 103 | 111 | 106 | 173 |
ROCE % | 38% | 26% |
Documents
Announcements
- Closure of Trading Window 1d
- Intimation Under Regulation 30 Of SEBI (LODR), 2015. 21 Jun
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
27 May - Copy of Annual Secretarial Compliance Report for the year ended March 31, 2024
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 May - Newspaper Publication of Standalone and Consolidated Audited Financial Results for the quarter and year ended March 31, 2024.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
14 May - Monitoring Agency Report for quarter ended March 31, 2024
Annual reports
No data available.
Business Profile[1] The company manufactures a single product, i.e., Paracetamol, which has several applications, like in treatment headache, muscle ache, arthritis, back ache, toothache, cold, and fever. Paracetamol is one of the most commonly taken analgesics worldwide and is recommended as the first-line therapy in pain conditions by the World Health Organization (WHO).